Anthony M. Insogna

Partner

Anthony Insogna has more than 20 years of experience representing clients in intellectual property matters including patent litigation, patent interferences, oppositions, patent portfolio creation and management, strategic counseling, technology transactions, and due diligence. He has prosecuted and enforced patents in the United States and coordinated prosecution and enforcement worldwide for some of the most successful therapeutics developed by pharmaceutical, biotechnology, and medical device companies. Anthony has significant experience with the patent and FDA laws under the Hatch-Waxman Act, and he regularly handles IP issues attendant to mergers, acquisitions, partnerships, collaborations, and financing for life sciences companies.

Representative clients include Acadia Pharmaceuticals, Ambit Biosciences, Amyris Biotechnologies, AstraZeneca, Celgene, Isis Pharmaceuticals, MedImmune, Mitsui Global Investments, PTC Therapeutics, Puma Biotechnology, Scynexis, Sunesis Pharmaceuticals, Sunovion (formerly Sepracor), as well as investment banks and other private equity firms. Anthony's experience includes patent portfolio creation, development and management, patent infringement actions, oppositions, patent interferences, invalidation proceedings, and transactions for products including Abraxane®, Allegra®, Brovana®, Clarinex®, Clofar®, Embospheres®, Ethyol®, Focalin®, Focalin XR®, HepaSpheres®, Lunesta®, Pristiq®, Relafen®, Rezield™, Revlimid®, Ritalin LA®, Synagis®, Thalomid®, Tyzeka®, Zytiga®, and others as well as many product candidates currently in clinical trials.

Anthony is co-chair of the Firm's Intellectual Property Practice.